EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond

Saurabh Kumar, Jocelyn A Schroeder, Qizhen Shi

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2023.07.025 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Saurabh Kumar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Blood Research Institute, Versiti Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health, Midwest Athletes Against Childhood Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blood platelets have unique storage and delivery capabilities. Platelets play fundamental roles in hemostasis, inflammatory reactions, and immune responses. Beyond their functions, platelets have been used as a target for gene therapy. Platelet-targeted gene therapy aims to deliver a sustained expression of neo-protein in vivo by genetically modifying the target cells, resulting in a cure for the disease. Even though there has been substantial progress in the field of gene therapy, the potential development of immune responses to transgene products or vectors remains a significant concern. Of note, multiple preclinical studies using platelet-specific lentiviral gene delivery to hematopoietic stem cells in hemophilia have demonstrated promising results with therapeutic levels of neo-protein that rescue the hemorrhagic bleeding phenotype and induce antigen-specific immune tolerance. Further studies using ovalbumin as a surrogate protein for platelet gene therapy have shown robust antigen-specific immune tolerance induced via peripheral clonal deletions of antigen-specific CD4- and CD8-T effector cells and induction of antigen-specific regulatory T (Treg) cells. This review discusses platelet-targeted gene therapy, focusing on immune tolerance induction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHumansBlood PlateletsGenetic TherapyImmune ToleranceHemostasisFactor VIII

Stichwörter der Autor:innen

gene therapyhemophilia Ahemophilia Bimmune toleranceplatelet

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Blood Research Institute, Versiti Wisconsin, Milwaukee, Wisconsin, USA.
  • Blood Research Institute, Versiti Wisconsin, Milwaukee, Wisconsin, USA; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Blood Research Institute, Versiti Wisconsin, Milwaukee, Wisconsin, USA; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; Children's Research Institute, Children's Wisconsin, Milwaukee,…

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health
  • Midwest Athletes Against Childhood Cancer

Zitieren

APA

Kumar, S., Schroeder, J. A., & Shi, Q. (2024). Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.07.025

Vancouver

Kumar S, Schroeder JA, Shi Q. Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2023.07.025

BibTeX
@article{Kumar2024,
  author = {Kumar, Saurabh and Schroeder, Jocelyn A and Shi, Qizhen},
  title = {Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2023.07.025}
}
Kostenlos starten →